Welcome to our dedicated page for Rain Enhancement news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement stock.
Rain Oncology Inc. (NasdaqGS: RAIN) is a clinical-stage biotechnology company developing precision therapies targeting specific cancer drivers. This news hub provides investors and researchers with timely updates on the company's progress in oncology innovation, including its lead candidate milademetan and strategic initiatives.
Access authoritative updates on clinical trial developments, regulatory milestones, and corporate announcements. The resource consolidates essential information about RAIN's therapeutic pipeline, financial position, and partnership activities – critical data points for evaluating the company's trajectory in precision medicine.
Key coverage areas include progress in Phase 3 MANTRA trials for liposarcoma, updates on tumor-agnostic basket studies, and analysis of strategic merger plans with Pathos AI. All content maintains rigorous standards for accuracy and clarity, serving both professional investors and those monitoring advancements in cancer treatment.
Bookmark this page for direct access to verified Rain Oncology announcements and objective reporting on developments impacting the company's scientific and financial progress.
Rain Therapeutics has expanded its leadership team with experienced professionals from notable firms such as Loxo/Lilly, Gilead, Seagen, and AltruBio. Key new appointments include Nora Ku as VP of Clinical Development, Buenaflor Nicolas as VP of Global Drug Safety, Tina Kim-Hafken as VP of Regulatory Affairs, and Steve Flint as VP of People & Culture. Additionally, John Maraganore continues as a Special Advisor since March 2021. These strategic hires aim to enhance Rain’s late-stage clinical and regulatory operations as they develop innovative cancer therapies, particularly the oral inhibitor milademetan.
Rain Therapeutics Inc. (NASDAQ: RAIN) will present a corporate overview at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 1:40 pm ET. CEO Avanish Vellanki will lead the presentation, followed by a Q&A session. The presentation will be available for replay on the Rain website for 30 days post-event. Rain specializes in precision oncology, targeting oncogenic drivers and selecting patients based on genetic profiles, with its lead candidate being milademetan, an MDM2 inhibitor effective in various cancers.
Rain Therapeutics Inc. (NASDAQ: RAIN) will participate in two upcoming virtual events. CEO Avanish Vellanki will present at the B. Riley Securities Oncology Investor Conference on January 27, 2022, at 3:30 pm ET. Additionally, Rain will be featured in a virtual fireside chat at the Guggenheim Oncology Conference on February 10, 2022, at 4:00 pm ET. Both events will provide insights into the company's precision oncology therapies, including their leading candidate, milademetan. Replays of these presentations will be available on Rain’s official website for 30 days post-event.
Rain Therapeutics Inc. has announced a clinical supply agreement with Roche to evaluate the combination of milademetan, an MDM2 inhibitor, with atezolizumab, a PD-L1 antibody, targeting genetically selected cancer patients. This agreement includes plans for a Phase 1 trial assessing safety and efficacy in patients with specific tumors, with a launch expected in the second half of 2022. Rain is also advancing milademetan's use in other ongoing trials for various cancers and has received FDA Orphan Drug Designation for liposarcoma.
Rain Therapeutics Inc. (NasdaqGS: RAIN) announced that CEO Avanish Vellanki will present at two upcoming virtual conferences: the JP Morgan Chase 40th Annual Healthcare Conference on January 13, 2022, and the H.C. Wainwright Bioconnect Conference starting January 10, 2022. The JP Morgan presentation will be live at 11:15 a.m. ET, while H.C. Wainwright will feature a prerecorded session available from 7:00 a.m. ET. Both events highlight Rain's focus on precision oncology, targeting therapies for genetically selected patients.
Rain Therapeutics Inc. (NASDAQ: RAIN) announced its inclusion in the NASDAQ Biotechnology Index (NBI), effective December 20, 2021. This index tracks NASDAQ-listed companies in the biotechnology and pharmaceuticals sector. To qualify, companies must have a market cap of at least $200 million and an average daily trading volume of 100,000 shares. Rain Therapeutics focuses on developing precision oncology therapies, including its lead candidate, milademetan, an oral MDM2 inhibitor targeting various cancers. This index inclusion may enhance visibility and investment interest in Rain.
Rain Therapeutics Inc. (NasdaqGS: RAIN) announced that its CEO, Avanish Vellanki, will partake in two upcoming virtual conferences: the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021, and the Evercore ISI 4th Annual Health CONx Virtual Conference on December 2, 2021. The Piper Sandler presentation will be available starting November 22, 2021, at 10:00 a.m. ET. Both events will include webcasts accessible through Rain's website, with replays available for 30 days post-presentation. Rain focuses on precision oncology, developing targeted therapies for cancer.
Rain Therapeutics has initiated the Phase 2 MANTRA-2 trial to assess the safety and efficacy of milademetan, an MDM2 inhibitor, in patients with MDM2-amplified advanced solid tumors. The trial aims to enroll approximately 65 patients refractory to standard therapies, focusing on wild-type p53 tumors. The primary endpoint is the objective response rate. Interim results are expected in late 2022. Milademetan has shown promise in earlier trials, including a Phase 1 study demonstrating anti-tumor activity in liposarcoma and other solid tumors.
Rain Therapeutics reported a net loss of $18.4 million for Q3 2021 and $33.4 million for the first nine months, compared to losses of $10.4 million and $15.6 million in the same periods of 2020. The company ended Q3 with $150.1 million in cash, providing a runway to advance clinical trials, including the MANTRA-3 trial for milademetan in Merkel cell carcinoma, set to start in mid-2022. R&D expenses rose to $15.3 million for Q3 2021, up from $7.9 million in Q3 2020. Milademetan shows promise in ongoing and upcoming trials, aiming for significant oncology advancements.
Rain Therapeutics (NASDAQ: RAIN) has announced the initiation of the MANTRA-3 Phase 2 clinical trial for milademetan as a treatment for Merkel cell carcinoma (MCC) in patients who are resistant to immunotherapy. The trial, set to start mid-2022, will enroll approximately 30 patients. The primary objective is to assess the objective response rate through RECIST criteria. This move comes after promising preclinical results and replaces a previously planned trial for intimal sarcoma. Rain will also host its first annual R&D Day webinar today to discuss relevant oncology research.
FAQ
What is the current stock price of Rain Enhancement (RAIN)?
What is the market cap of Rain Enhancement (RAIN)?
